|
Wednesday, 2 April 2003: 12:00-13:30 |
Room I (CICG) |
Poster Session 1 |
|
| | | | 101 Non-Cognitive Markers of Early Dementia: Awareness and Self in Mild Cognitive Impairment (MCI)
Louisa Fischer-Altevogt, Pasquale Calabrese |
| | | | 102 Proton NMR Spectroscopy in Mild Cognitive Impairment: Early Right Hippocampal Involvement
Maria Theresa Caserta, Ann Ragin, Adriana Hermida |
| | | | 103 The rehabilitation for demented patients: a new nursing care approach focused on mental representations
mercedes Pindado, Agnes Michon |
| | | | 104 Development of Screening Guidelines and Clinical Criteria for Predementia AD. The DESCRIPA Study
Pieter Jelle Visser, Frans Verhey |
| | | | 105 The Vascular Lesions in Vascular and Mixed Dementia: The Weight of Functional Neuroanatomy
Dina Zekry, Charles Duyckaerts, Joel Belmin, Caroline Geoffre, Robert Moulias, Jean-Jacques Hauw |
| | | | 106 The Importance of Visual Evoked Potential Examinations in Vascular Dementia (VD)
Dimitrios Kountouris |
| | | | 108 Etiology and Clinical Characteristics of Epilepsy in the Eldery
Emilija Cvetkovska, Igor Kuzmanovski, Mihail Pashu |
| | | | 109 Factors Influencing the Prescribing of Atypical Antipsychotic Pharmacotherapy: Does Age Matter?
David A. Sclar, Tracy L. Skaer, Linda M. Robison, Michael W. Dickson, C. Lindsay DeVane, John S. Markowitz |
| | | | 111 Institutionalized Elders with Depressive Illness Treated with Sertralin: Dose-Response Correlation
Pere Batlle Izard, Jordi Esquirol Caussa, Elisabeth Herrero Vila, José Sánchez Aldeguer, Joan Mogas García |
| | | | 112 Cognition is Physicians’ Main Indicator of Treatment Efficacy in Alzheimer’s Disease Patients
S Hasselbalch, H Hampel, CJ Kalisvaart, W Kozubski, E Salmon, H Tilker, F Túry, V Vagenas, L Johansen, Y Xu, S Richardson, N Kumar, P Johannsen |
| | | | 113 Reducing Prescribing of Long-Acting Benzodiazepines in a Large Community Veteran Population
Michael Woodward, C Streeton, K Henshaw, G Killer, R Peck |
| | | | 114 Factors that Affect Compliance Behavior in Psychogeriatric Outpatients
Theocharis Mavridis, Anastasia Konsta, Demetrios Kandilis, Apostolos Iacovidis, George St Kaprinis |
| | | | 115 Therapeutic Drug Monitoring in Depressive Elderly
Joanna Ewa Wilkowska, Maria Radziwoñ- Zaleska, Halina Matsumoto, Micha³ Skalski, Daria Matoszko, Wojciech Androsiuk, Andrzej Wakarow, Jadwiga Piwowarska, Agnieszka Zieliñska, Jacek £ukaszkiewicz, Anna Dzikliñska, Julita Kuczyñska, Pawe³ K. Kunicki, Jan Pachecka, Waldemar Szelenberger |
| | | | 117 Cognitive Enhancers and Potassium Channels
Elena Solntseva, Julia Bukanova |
| | | | 118 Galantamine Significantly Improves Behavioral Symptoms and Reduces Caregiver Distress in Mild-to-Moderate Alzheimer’s Disease
Andreas U. Monsch, Ingrid Heiter-Reiffenstuhl, Daniel Braendle |
| | | | 119 Galantamine Shows Significant Long-term Benefits on Cognitive and Functional Performance in Advanced Moderate Alzheimer’s Disease
Susanne Schwalen, Gerry Hammond |
| | | | 120 The long-term treatment response in patients with moderate-to-severe Alzheimer’s disease: galantamine vs. donepezil
Ian McKeith, Keith Wesnes, Gerry Hammond, Sean Lilienfeld |
| | | | 121 Cerebral Glucose Metabolism Study (PET) Suggests a Link Between the Clinical Efficacy of Galantamine and its Nicotinic Receptor Modulating Effects
Ruediger Mielke, Claus Weichel, Alfred Maelicke |
| | | | 122 Donepezil in Alzheimer's Disease: 3 Months Versus 6 Months Evaluation of Treatment Response
Harald Hampel, Pasquale Calabrese, Martin Kamleiter, Lutz Froelich, Klaus Hager, Frank M Berger |
| | | | 123 The Efficacy and Neuroprotective Effects of Galantamine in Alzheimer’s Disease are Associated with the Nicotinic Receptor Modulation
Hugo Geerts, Manuela Garcia |
| | | | 124 Consistently Small “Number-Needed-to-Treat” (NNT) in Galantamine Treated Patients with “Advanced Moderate” Alzheimer’s Disease
Susanne Schwalen, Gerry Hammond, Michael Davidson |
| | | | 125 Galantamine Maintains Cognitive Functions Long-term Above Baseline in Mild Alzheimer’s Disease
Christoph JG Lang, Tanja Leuschner, Susanne Schwalen |
| | | | 126 Will It Work? Should People with Moderate to Severe Alzheimer's Disease Be Treated with a Cholinesterase Inhibitor?
Theodore Dreier |
| | | | 128 Galantamine Provides Long-term Benefits on Cognition in Alzheimer’s Disease over 4 Years
Susanne Schwalen, Gerry Hammond |
| | | | 129 Wandering Behavior of Institutionalized Patients with Alzheimer's Disease
Keiko Sugano, Noriko Kamakura, Tatsuo Hatta, Munehiro Ikuta |
| | | | 130 Agitated Behaviors in Dementia: How Are They Tolerated by Caregivers ?
Sylvie Bonin-Guillaume, Catherine Molines, Vincent Rouzaud, Yves Frances, Marc Heim |
| | | | 131 Clustering of Behavioural Symptoms in Alzheimer’s Disease
Maria Moran, Cathal Walsh, Brian A Lawlor |
| | | | 132 Exploring the Loss and Preservation of Abilities Among Persons Diagnosed with Probable Dementia
Richard B. Ferrell, Robert B. Williams |